Activist investor Jana Partners has taken a significant stake in Cooper Companies (COO) and is pushing for strategic alternatives to unlock shareholder value, following the company's recent underperformance, including a 12.85% stock drop after lowered guidance. Jana's core thesis advocates for separating Cooper's two distinct businesses, CooperVision (contact lenses) and CooperSurgical (women's health), arguing that investments in the latter have diluted overall returns and led to a valuation discount. The activist proposes a potential combination of CooperVision with peers like Bausch + Lomb, citing low antitrust risk and significant synergy potential, while suggesting a spin-off or sale of CooperSurgical, aiming to address COO's current 16.4x forward P/E, which is well below its 10-year average of 23.1x.
Jana Partners has initiated an activist campaign at Cooper Companies (COO), taking a top portfolio position to advocate for strategic alternatives. Their core thesis centers on separating CooperVision (contact lenses) and CooperSurgical (women's health), arguing the current structure leads to a valuation discount. Jana highlights that over $3 billion in investments in CooperSurgical since 2017 have resulted in declining returns on capital and lower margins for that segment, diverting cash from the higher-margin CooperVision business. The company's recent performance has been challenged, with Q3 organic growth falling to 2% from 7% in the prior quarter, leading to a significant reduction in full-year guidance and a 12.85% stock price drop. This underperformance stems from a mismanaged MyDay Energys lens rollout and a slowdown in CooperSurgical's IVF business. Consequently, COO trades at a 12-month forward P/E of 16.4x, a substantial discount to its 10-year average of 23.1x, reflecting market skepticism. Jana proposes combining CooperVision with a peer like Bausch + Lomb (BLCO) or EssilorLuxottica, citing low antitrust risk and potential synergies of $300 million to $500 million. For CooperSurgical, private equity interest is anticipated, or internal restructuring could unlock value by focusing on the higher-multiple IVF business. The success of Jana's campaign depends on convincing current management, potentially escalating to a leadership/governance challenge.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Overall Sentiment
mixed
Sentiment Score
0.00
Ticker Sentiment
